MMV and Merck & Co. to develop promising antimalarial compound
A promising antimalarial candidate discovered by Merck & Co. will be developed in partnership with MMV. The candidate is an orally available compound, which could potentially provide a daily or twice-daily curative dosing regimen. MMV welcomes this opportunity to move research on this exciting candidate into the clinical development phase.
WHITEHOUSE STATION N.J., and GENEVA, March 18, 2009 - Merck & Co., Inc. and Medicines for Malaria Venture (MMV), a not-for-profit virtual research and development organization dedicated to reducing the burden of malaria, today announced a licensing agreement for an investigational drug candidate for the treatment of malaria in the developing world.
Under terms of the agreement, Merck, whose researchers discovered the candidate, has granted MMV an exclusive, royalty-free license to pursue development of the investigational candidate for the treatment of malaria in malaria-endemic countries. Merck retains the option to become MMV’s development partner upon completion of the first Phase II clinical trial of the candidate. Also within the agreement Merck has committed to not ultimately profiting from its use in developing countries.
"There remains a significant need for the development of novel drugs to treat and prevent life-threatening malaria infections due to the increasing emergence of resistance to current therapies. It is also important that these new drugs are cost-effective and curative after only a few days of therapy," said Dennis M. Schmatz, Ph.D., vice president Merck Research Laboratories. "By partnering with MMV on this project we hope to accelerate the clinical development of this promising candidate to hopefully meet these needs."
“Malaria researchers are working round the clock to develop new medicines to stem the unacceptable loss of life due to this deadly disease,” said Dr. Chris Hentschel, president and chief executive officer of MMV. "MMV welcomes this opportunity to work with Merck and to move research on this exciting antimalarial candidate into the development phase. The more treatments we can develop against the deadly malaria parasite the closer we will get to its ultimate eradication"
The antimalarial candidate is an orally available compound, which could potentially provide a daily or twice-daily curative dosing regimen. In preclinical studies, it has shown to be effective against P. falciparum, the organism that causes acute malaria, including multi-drug resistant strains. The compound is produced via relatively simple chemical synthesis and demonstrates a high degree of stability. For these reasons, it is anticipated that, if shown to be effective in treating malaria in humans, it should be possible to produce large quantities of the drug at low cost. Given the magnitude of the global malaria challenge, it is essential that effective drugs can be produced in sufficient quantities and at an affordable price to enable availability in the world’s poorest countries.
Preclinical safety and efficacy evaluation of the antimalarial drug candidate has been completed, and it is now ready to be advanced to clinical studies evaluating its safety and efficacy in humans. MMV will be responsible for the clinical program at this stage and representatives from Merck will be included as members of the advisory board for the project.
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck’s business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck’s Form 10-K for the year ended Dec. 31, 2008, and in any risk factors or cautionary statements contained in the Company’s periodic reports on Form 10-Q or current reports on Form 8-K, which the Company incorporates by reference.